Equity · Healthcare
TRVI
Trevi Therapeutics, Inc. · NasdaqGM
The line runs $13.88 on 20 May through $19 on 17 July, on a scale from $12 to $20. Days the market did not trade hold the previous close, flat.
The chart above plots the price of TRVI over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $13.88 on 20 May 2026 through $19 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
TRVI insider trades
TRVI has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 2 December 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
TRVI reported financials
TRVI reported net income of −$42.8M for the fiscal year ended 31 Dec 2025.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
TRVI earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
TRVI institutional holders
5 of the 45 institutional funds we track reported a TRVI position for the quarter ended 30 Jun 2026 — a combined $101.1M; the latest of those filings landed 14 Aug 2026.
Source: SEC EDGAR 13F filings
TRVI fails-to-deliver
On 24 Jul 2026, 281 shares of TRVI failed to deliver (about $5K) — the latest of 3 consecutive trading days with recorded fails.
Source: SEC fails-to-deliver (CNS) data